Allied Market Research


Obsessive Compulsive Disorder (ocd) Drug Market

Obsessive Compulsive Disorder (OCD) Drug Market Size, Share, Competitive Landscape and Trend Analysis Report by Therapy Type, by Symptoms Type and by Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Obsessive Compulsive Disorder Drug Market Overview 2030

Obsessive compulsive disorder is a behavioral or mental disorder in which person has certain thoughts repeatedly or perform certain routines repeatedly. The person who is suffering from this disorder is unable to control his thoughts and activities in short period of time. Excessive hand washing, counting things, and checking to see if a door is locked are most common symptoms of obsessive compulsive disorder. This medical condition is associated with tics, anxiety disorder, and rise in risk of suicide. Selective serotonin reuptake inhibitors, antidepressants, antipsychotics, antianxiety, and others are prescribed to the patient for treatment of this disease. Moreover, clomipramine, aripiprazole, dextroamphetamine, risperidone, and olanzapine are the drugs which can be used in treatment of the obsessive compulsive disorder.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the obsessive compulsion disorder drug market.

Top Impacting Factors

  • Increase in incidence of stress and anxiety, rise in cases of infectious diseases across the globe, surge in number of people suffering from brain trauma, increase in demand for targeted drug therapies, and surge in awareness regarding early diagnosis of diseases are the major factors that drive the growth of market.
  • In addition, increase in adoption of advance healthcare devices, rise in development in obsessive compulsive disorder treatment procedures, surge in demand for off-level drugs & therapies, increase in R & D activities for launch of approved obsessive compulsive disorder treatment drugs, and surge in investment of healthcare sector are some factors that fuel the growth of market.
  • However, side effects related use of obsessive compulsive disorder drugs and generic versions of branded drugs restrain the growth of market.
  • Contrarily, increase in government support to spread awareness regarding treatment of obsessive compulsive disorder is expected to offer lucrative opportunities for the expansion of the market.

Market Trends

New Product Launches to Flourish the Market

In 2019, Lupin announced launch of antidepressant tablets in U.S. This tablet contain 10 mg / 20 mg Fluoxetine which can be used in treatment of obsessive compulsive disorder and bulimia nervosa.

In 2019, Lupin announced approval of U.S. Food and Drug Administration for launch of Anafranil capsules. This product contain Clomipramine which can be used in treatment of obsessive compulsive disorder.

In 2019, Upsher Smith launched generic version of Prozac Fluoxetine tablets in U.S. market. This drug help in treatment of obsessive compulsive disorder.

Key Benefits of the Report

  • This study presents the analytical depiction of obsessive compulsion disorder drug market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Obsessive Compulsion Disorder Drug Market Report             

  • Which are the leading players active in the obsessive compulsion disorder drug market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "obsessive compulsion disorder drug"?
  • What is "obsessive compulsion disorder drug" market prediction in the future?
  • Who are the leading global players in the "obsessive compulsion disorder drug" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "obsessive compulsion disorder drug" market report?

Obsessive Compulsive Disorder (OCD) Drug Market Report Highlights

Aspects Details
By Therapy Type
  • Contamination Obessions
  • Checking Compulsions
  • Obessions Without Visible Complusions
  • Symmetery Obessions with Ordering Complusions
  • Hoarding
By Symptoms Type
  • Cognitive Behavioural Therapy
  • Augmentation Therapy
  • Aversion Therapy
  • Systematic Desensitization
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players

Sanofi, Brainsway, Novartis AG, Zydus Cadila., Addex therapeutics, Eli Lilly and Company, Omeros Corporation, Pfizer Inc., AstraZeneca, AbbVie Inc., F. Hoffmann-La Roche Ltd, Abbott, C4x discovery holdings plc., Sellas, Meiji Holdings Co., Ltd, Merck & Co., Inc., Mylan N.V.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Obsessive Compulsive Disorder (OCD) Drug Market

Global Opportunity Analysis and Industry Forecast, 2023-2032